Abstract
Lenalidomide is an immunomodulatory agent which has been approved for multiple myeloma. Lenalidomide is also effective in and tolerated well by patients with follicular lymphoma, diffuse large B-cell lymphoma, and transformed large cell lymphoma. This review summarizes the results of current preclinical and clinical studies of lenalidomide, alone or in combination with the monoclonal antibody rituximab, as a therapeutic option for these three lymphoma types. This review will serve as a tool guiding future clinical investigations to improve survival rates for these three lymphomas.
MeSH terms
-
Angiogenesis Inhibitors / administration & dosage
-
Angiogenesis Inhibitors / adverse effects
-
Angiogenesis Inhibitors / therapeutic use*
-
Animals
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Humans
-
Immunomodulation
-
Lenalidomide
-
Lymphoma, Large B-Cell, Diffuse / drug therapy*
-
Lymphoma, Large B-Cell, Diffuse / immunology
-
Thalidomide / administration & dosage
-
Thalidomide / adverse effects
-
Thalidomide / analogs & derivatives*
-
Thalidomide / therapeutic use
-
Tumor Microenvironment
Substances
-
Angiogenesis Inhibitors
-
Thalidomide
-
Lenalidomide